Daily intake of Mucuna pruriens in advanced Parkinson's disease: A 16-week, noninferiority, randomized, crossover, pilot study
Cilia R, Laguna J, Cassani E, Cereda E, Raspini B, Barichella M, Pezzoli G
Published in Parkinsonism & Related Disorders
Methodology
Randomized crossover noninferiority pilot trial comparing Mucuna pruriens seed powder with marketed levodopa/carbidopa in Parkinson's patients with motor fluctuations
Key Findings
In those who tolerated MP, clinical response was similar to levodopa/carbidopa on all efficacy outcomes, but 50% discontinued MP early due to gastrointestinal side-effects or worsening motor performance.
Conclusions
Benefit of Mucuna pruriens was limited by tolerability rather than efficacy; larger parallel-group studies are needed to define formulation and dosing.
Limitations
Very small pilot sample, high dropout, open switch from levodopa/carbidopa, single-centre
Supplements Studied
In those who tolerated MP, clinical response to MP was similar to LD/CD on all efficacy outcome measures.
Outcomes Measured
In those who tolerated MP, clinical response to MP was similar to LD/CD on all efficacy outcome measures.
Study Details
Access Study
Disclosures
Funding
Not reported
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.